Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Six RNAi-Related Patent Applications: Jul 5, 2007

Title: RNAi-Mediated Inhibition of Rho Kinase for Treatment of Ocular Disorders
Number: 20070149473
Filed: Dec. 19, 2006
Lead Inventor: Jon Chatterton, Alcon
The patent application, according to its abstract, claims “RNA interference … for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.”

Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
Number: 20070149471
Filed: Sept. 8, 2006
Lead Inventor: Sam Reich, Opko Health
According to the patent application’s abstract, “RNA interference using small interfering RNAs [that] are specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”

Title: Inhibition of Viral Gene Expression Using Small Interfering RNA
Number: 20070149470
Filed: June 1, 2006
Lead Inventor: Roger Kaspar, Somagenics
“The invention provides methods, compositions, and kits comprising small interfering RNA that are useful for inhibition of viral-mediated gene expression,” the patent application’s abstract states. “Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targeting the internal ribosome entry site sequence of HCV are described.”

Title: Partial Inhibition of Influenza Virus by Specifically Designed Short Interfering RNA
Numbers: 20070148134,20070148133
Filed: Feb. 15, 2007
Lead Inventor: Bijay Pal, California State Polytechnic University
“This patent application discloses siRNA sequences against [a] constant region of the influenza virus nucleoprotein,” its abstract states. “The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans,” it adds. “In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans. The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.”

Title: Tetracycline-Regulated Adeno-Associated Viral Vectors for Gene Delivery to the Nervous System
Number: 20070148132
Filed: Nov. 15, 2006
Lead Inventor: Martha Bohn, Northwestern University
According to the patent application’s abstract, the invention comprises “a vector and a method … for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first nucleic acid and a second promoter operably linked to the second nucleic acid. The promoters drive expression in opposite directions and away from the inverted terminal repeats. The method includes providing a recombinant adeno-associated viral (rAAV) vector and administering the vector to a nervous system cell. Expression of a product from the first nucleic acid is regulatable by the promoter system.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.